Lantheus (NASDAQ:LNTH) Price Target Raised to $98.00 at Truist Financial

Lantheus (NASDAQ:LNTH) had its price target boosted by Truist Financial from $89.00 to $98.00 in a report released on Wednesday, MarketBeat.com reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

Several other research firms have also recently weighed in on LNTH. JonesTrading cut Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. William Blair restated an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Citizens Jmp upped their target price on Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a research note on Tuesday, February 24th. Finally, Wall Street Zen upgraded Lantheus from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 28th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and an average target price of $88.86.

Lantheus Stock Up 1.5%

LNTH opened at $83.94 on Wednesday. Lantheus has a 1-year low of $47.25 and a 1-year high of $108.91. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $5.46 billion, a price-to-earnings ratio of 24.91 and a beta of -0.12. The business has a 50 day moving average of $75.60 and a 200-day moving average of $65.75.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.50. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.The company had revenue of $406.79 million during the quarter, compared to analysts’ expectations of $367.03 million. During the same period in the prior year, the business earned $1.59 earnings per share. Lantheus’s revenue for the quarter was up 4.0% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, sell-side analysts anticipate that Lantheus will post 6.01 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Smartleaf Asset Management LLC lifted its holdings in shares of Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 197 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Lantheus by 30.3% during the 4th quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock valued at $66,000 after purchasing an additional 230 shares in the last quarter. Vident Advisory LLC lifted its holdings in shares of Lantheus by 0.5% during the 4th quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock valued at $2,979,000 after purchasing an additional 230 shares in the last quarter. United Community Bank lifted its holdings in shares of Lantheus by 15.6% during the 3rd quarter. United Community Bank now owns 1,815 shares of the medical equipment provider’s stock valued at $93,000 after purchasing an additional 245 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Lantheus by 71.4% during the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 275 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.